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SUMMARY
Low protein synthesis is a feature of somatic stem cells that promotes regeneration in multiple 
tissues. Modest increases in protein synthesis impair stem cell function, but the mechanisms by 
which this occurs are largely unknown. We determine that low protein synthesis within 
hematopoietic stem cells (HSCs) is associated with elevated proteome quality in vivo. HSCs 
contain less misfolded and unfolded proteins than myeloid progenitors. Increases in protein 
synthesis cause HSCs to accumulate misfolded and unfolded proteins. To test how proteome 
quality affects HSCs, we examine Aarssti/sti mice that harbor a tRNA editing defect that increases 
amino acid misincorporation. Aarssti/sti mice exhibit reduced HSC numbers, increased 
proliferation, and diminished serial reconstituting activity. Misfolded proteins overwhelm the 
proteasome within Aarssti/sti HSCs, which is associated with increased c-Myc abundance. Deletion 
of one Myc allele partially rescues serial reconstitution defects in Aarssti/sti HSCs. Thus, HSCs are 
dependent on low protein synthesis to maintain proteostasis, which promotes their self-renewal.
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Stem cells in multiple tissues depend on low protein synthesis to promote regeneration. Hidalgo 
San Jose et al. demonstrate that low protein synthesis promotes hematopoietic stem cell function 
by restricting the biogenesis of misfolded proteins. Misfolded proteins impair stem cell quiescence 
and self-renewal by overwhelming the proteasome and disrupting proteostasis.
Graphical Abstract
INTRODUCTION
Adult hematopoietic stem cells (HSCs) synthesize less protein per hour than most other 
hematopoietic progenitors. This does not simply reflect HSC quiescence because dividing 
HSCs also have lower rates of protein synthesis than dividing restricted progenitors (Signer 
et al., 2014). Low protein synthesis is necessary for HSC maintenance, as genetic changes 
that modestly increase protein synthesis impair HSC function (Goncalves et al., 2016; 
Signer et al., 2014, 2016). Somatic stem cells in multiple other adult tissues also have 
relatively low rates of protein synthesis, and this is often necessary for stem cell 
maintenance (Blanco et al., 2016; Llorens-Bobadilla et al., 2015; Sanchez et al., 2016; 
Zismanov et al., 2016). This raises a fundamental question of why low protein synthesis is 
necessary for stem cell maintenance and tissue regeneration.
Translation is the most error-prone step in gene expression. Translational errors can lead to 
protein misfolding and the formation of toxic aggregates. High rates of protein synthesis can 
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increase amino acid misincorporation (Drummond and Wilke, 2009). Reducing translation 
decreases the synthesis of defective translational products and promotes the clearance of 
misfolded proteins (Sherman and Qian, 2013). Based on these observations, we 
hypothesized that low protein synthesis could promote HSC maintenance and function by 
enhancing proteome quality, which we define as limiting the abundance of mistranslated, 
unfolded, and/or misfolded proteins. In this study, we set out to examine the effect of protein 
synthesis rates on proteome quality within HSCs in vivo and to test the consequences of 
reducing protein quality on HSC function.
RESULTS
HSCs Contain Less Ubiquitylated and Unfolded Protein Than Myeloid Progenitors
To assess proteome quality within hematopoietic stem and progenitor cells, we measured the 
abundance of ubiquitylated protein by western blot. Ubiquitylated protein includes an 
abundance of mistranslated or damaged proteins that misfold and are targeted for 
degradation (Duttler et al., 2013; Kim et al., 2011; Wang et al., 2013). As a consequence, 
ubiquitylated protein is widely used to assess the abundance of misfolded and unfolded 
proteins (Kim et al., 2011; Lee et al., 2006; Schubert et al., 2000). To obtain enough cells for 
western blot analyses, we typically pooled CD150+CD48−Lineage−Sca-1+c-kit+ 
(CD150+CD48−LSK) HSCs (Kiel et al., 2005) and CD150−CD48−LSK multipotent 
progenitors (MPPs) (Oguro et al., 2013). HSCs and this population of MPPs (which are 
sometimes referred to as short-term HSCs) are very similar in terms of their gene expression 
profile (Signer et al., 2016), cell cycle status (Oguro et al., 2013), protein synthesis rate 
(Signer et al., 2014), and metabolism (Agathocleous et al., 2017). CD48−LSK HSCs/ MPPs 
contained considerably less ubiquitylated protein and less LysK48-linkage specific 
polyubiquitylated protein (which preferentially targets substrates for degradation) than equal 
numbers of common myeloid progenitors (CMPs), granulocyte macrophage progenitors 
(GMPs) and megakaryocyte erythroid progenitors (MEPs) (Akashi et al., 2000) isolated 
from the bone marrow of young adult mice (Figures 1A and S1A).
Unfortunately, it is not possible to develop western blots with all ubiquitylated protein 
within the linear range of exposure, which precludes accurate quantification. To circumvent 
this limitation, we quantified ubiquitylated protein by intracellular flow cytometry using an 
antibody that preferentially recognizes polyubiquitin chains and exhibits no 
immunoreactivity with free ubiquitin (Markmiller et al., 2019). HSCs contained significantly 
less ubiquitylated protein than CMPs (47%; p < 0.01), GMPs (157%; p < 0.001), and MEPs 
(57%; p < 0.001) (Figures 1B and 1C).
Differences in ubiquitylated protein could not be explained by differences in cell volume, 
total protein abundance, or proteasome activity. Cell volume was similar between HSCs and 
CMPs (Figure 1D) despite HSCs having significantly less ubiquitylated protein (Figure 1B). 
Restricted progenitors also contained similar amounts of total protein as HSCs (Figure 1E 
and 1F), and HSCs had significantly less ubiquitylated protein than restricted progenitors 
even when normalized to total protein abundance (Figure 1G). HSCs also exhibited much 
less proteasome activity than CMPs (10-fold; p < 0.001), GMPs (132-fold; p < 0.001) 
(Signer et al., 2016), and MEPs (6.5-fold; p < 0.01) (Figure 3F).
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Although ubiquitylated protein is used as a surrogate to quantify misfolded and unfolded 
proteins (Lee et al., 2006; Sontag et al., 2014; Vilchez et al., 2012), not all ubiquitylated 
protein arises from misfolding events. We thus sought an orthogonal assay to measure 
protein quality. Tetraphenylethene maleimide (TMI) is a cell-permeable dye that fluoresces 
upon binding to cysteine thiols (Chen et al., 2017). The free thiol side chains of non-
disulphide-bonded hydrophobic cysteines are typically buried within the core of globular 
proteins (Marino and Gladyshev, 2010) but can be exposed in unfolded proteins (Figure 1H). 
We adapted TMI to quantify unfolded proteins within single hematopoietic cells by flow 
cytometry. Hematopoietic cells treated with TMI exhibited a clear increase in fluorescence 
relative to untreated controls (Figure S1B). Although glutathione represents a major pool of 
non-protein thiols within cells, it does not induce TMI fluorescence (Chen et al., 2017). 
Furthermore, glutathione levels do not significantly differ between HSCs and restricted 
progenitors (Agathocleous et al., 2017).
To validate TMI fluorescence as a reporter of unfolded protein accumulation in 
hematopoietic cells, we performed several independent experiments. First, we assessed the 
effect of heat shock, which induces protein unfolding (Morimoto, 2011), on TMI 
fluorescence in bone marrow cells. Bone marrow cells incubated at 42°C for 4 h exhibited a 
22% increase in TMI fluorescence relative to an aliquot of the same cells incubated at 37°C 
(Figures 1I and S1B; p < 0.05). Heat-shocked bone marrow cells had statistically equivalent 
amounts of total protein compared to bone marrow cells incubated at 37°C (Figure 1J), 
indicating that differences in TMI fluorescence do not simply reflect differences in total 
protein abundance. Next, because unfolded proteins are primarily degraded by the 
proteasome, we assessed the effects of proteasome inhibition on TMI fluorescence in vivo. 
Bone marrow cells isolated from mice treated with the proteasome inhibitor bortezomib 
exhibited a ~30% increase in TMI fluorescence compared to cells from vehicle-treated 
controls (Figures 1K and S1C; p < 0.05). Finally, we compared levels of ubiquitylated 
protein within TMIlow (lowest quartile of TMI fluorescence), TMIhigh (highest quartile of 
TMI fluorescence), and unfractionated bone marrow cells by western blot. TMIlow bone 
marrow cells contained less ubiquitylated protein than unfractionated bone marrow cells, 
which in turn contained less ubiquitylated protein than TMIhigh bone marrow cells (Figure 
S1D). These data suggest that TMI fluorescence accurately reflects the amount of unfolded 
proteins within primary hematopoietic cells.
The mean fluorescence intensity of TMI was significantly lower in HSCs than CMPs (32%; 
p < 0.01), GMPs (25%; p < 0.05), and MEPs (48%; p < 0.01) (Figures 1L and S1E–S1K). 
Although these differences appear rather modest, the increase in TMI fluorescence in 
restricted progenitors compared to HSCs was similar or greater in magnitude to that 
observed in bone marrow cells following either heat shock (Figure 1I) or bortezomib 
administration (Figure 1K), which are both treatments that significantly disrupt proteostasis. 
Overall, these data suggest that HSCs contain significantly elevated proteome quality 
compared to restricted myeloid progenitors in vivo.
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Increasing Protein Synthesis Reduces Protein Quality within HSCs In Vivo
Adult HSCs exhibit unusually low protein synthesis compared to other hematopoietic cells 
(Figure 1M; Hidalgo San Jose and Signer, 2019; Signer et al., 2014). Translation is the most 
error-prone step in gene expression, and 10%−30% of all newly synthesized proteins are 
ubiquitylated and targeted for degradation (Lykke-Andersen and Bennett, 2014; Schubert et 
al., 2000). This raises the question of whether low protein synthesis in HSCs contributes to 
their reduced abundance of ubiquitylated and unfolded protein in vivo.
To test if increasing protein synthesis reduces proteome quality within HSCs, we took 
advantage of two genetic mouse models that modestly alter protein synthesis rates within 
HSCs in vivo. Conditional deletion of Pten from adult hematopoietic cells in Mx1-
Cre;Ptenfl/fl mice leads to hyperactivation of the PI3K and mTor signaling pathways, which 
increases protein synthesis by ~30% in HSCs (Signer et al., 2014). Introduction of a 
ribosomal mutation (Rpl24Bst/+) (Oliver et al., 2004) functionally blocks this increase in 
protein synthesis within Pten-deficient HSCs without reducing hyperactivation of the 
downstream signaling pathways (Figure 1N; Signer et al., 2014). Increased protein synthesis 
within Pten-deficient HSCs was accompanied by an accumulation of ubiquitylated (Figure 
1O) and unfolded protein (Figure 1P; ~30%; p < 0.05) relative to controls. Rpl24Bst/+, which 
blocks the increase in protein synthesis (Signer et al., 2014), also blocked the increase in 
ubiquitylated and unfolded protein in Pten-deficient HSCs (Figures 1O and 1P). These data 
indicate that increased protein synthesis reduces protein quality within HSCs in vivo and 
suggests that HSCs depend upon low protein synthesis to maintain the integrity of their 
proteome.
Defects in tRNA Editing Preferentially Impair HSC Self-Renewal
We previously demonstrated that conditional deletion of Pten increases protein synthesis and 
severely impairs HSC function. Blocking the increase in protein synthesis with the 
Rpl24Bst/+ mutation largely rescues the function of Pten-deficient HSCs (Signer et al., 
2014). These data indicate that increased protein synthesis impairs HSC function. Consistent 
with these observations, other genetic interventions that modestly increase protein synthesis 
within HSCs, such as deletion of Eif4ebp1 and Eif4ebp2 (Signer et al., 2016) or deletion of 
Angiogenin (Goncalves et al., 2016), also impair HSC function.
Given that increased protein synthesis impairs HSC function and reduces proteome quality 
(Figures 1O and 1P), it raised the question of whether the accumulation of misfolded and 
unfolded proteins contributes to HSC dysfunction. To test this, we sought a mouse model 
that could decouple increased protein synthesis and reduced protein quality. Aarssti/sti mice 
harbor a mutation in the alanyl-tRNA synthetase that causes a tRNA editing defect that 
increases amino acid misincorporation at alanine residues, which can lead to an 
accumulation of mistranslated and ubiquitylated proteins within slowly and non-dividing 
cells (Lee et al., 2006). Aarssti/sti mice exhibit some skin and hair texture defects as well as 
age-related neurological defects (Lee et al., 2006). Despite these defects, Aarssti/sti mice are 
otherwise grossly normal and survive into adulthood. Aarssti/sti HSCs had an 18% increase 
in ubiquitylated protein compared to littermate control HSCs (Figures 2A and 2B; p < 0.01). 
Notably, the accumulation of ubiquitylated protein in Aarssti/sti HSCs occurred without 
Jose et al. Page 5
Cell Rep. Author manuscript; available in PMC 2020 February 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
significant changes in overall protein synthesis (Figure 2C), cell size (Figure S2A) or 
proteasome activity (Figure 3I). Furthermore, the increase in ubiquitylated protein within 
Aarssti/sti HSCs was within the physiological range observed within restricted progenitors 
(Figure S3A), making Aarssti/sti HSCs more similar to other hematopoietic cells. These data 
establish Aarssti/sti mice as a model to study the effects of a physiological decline in protein 
quality in vivo that is independent of changes in protein synthesis rate.
To assess the effects of reduced protein quality on hematopoiesis, we analyzed 8-week-old 
Aarssti/sti and littermate control mice. Aarssti/sti mice had normal bone marrow cellularity 
(Figure 2D) but significantly reduced spleen cellularity (Figure S2I) compared to controls. 
The frequency and absolute numbers of HSCs were significantly reduced by ~40% in the 
bone marrow of Aarssti/sti mice (Figures 2E and 2F; p < 0.01). The decline in HSCs was not 
due to mobilization to the spleen, as Aarssti/sti mice did not exhibit an increase in spleen 
HSCs (Figure 2G). In contrast to HSCs, the frequencies of CMPs, GMPs, MEPs, 
CD71+Ter119+ erythroid progenitors, CD11b+Gr1+ myeloid cells, pro-B cells, pre-B cells, 
IgM+ B cells, CD4+ T cells, and CD8+ T cells were unchanged in the bone marrow and 
spleen of Aarssti/sti mice compared to controls (Figures 2H–2J and S2B–S2P). The 
frequency of colony-forming progenitors was also unchanged in Aarssti/sti mice (Figure 2K). 
These data indicate that reduced protein quality in Aarssti/sti mice impairs the maintenance of 
HSCs but does not significantly impact the maintenance of restricted hematopoietic 
progenitors.
To test if reduced protein quality impairs HSC function, we performed serial long-term 
reconstitution assays. We competitively transplanted 10 CD150+CD48−LSK HSCs from 
Aarssti/sti or littermate control mice (CD45.2+) together with 2 × 105 wild-type congenic 
(CD45.1+) bone marrow cells into lethally irradiated mice (CD45.1+) (Figure 2L). Overall, 
long-term hematopoietic reconstitution from Aarssti/sti HSCs was statistically 
indistinguishable from controls in primary recipients (Figure 2M). After 16 weeks, 3 × 106 
bone marrow cells from primary recipient mice were serially transplanted into lethally 
irradiated mice. Secondary recipients of Aarssti/sti HSCs exhibited significantly less donor 
cell reconstitution after transplantation (Figure 2N). None (0/8) of the secondary recipients 
of Aarssti/sti HSCs exhibited long-term multilineage reconstitution compared to 67% (6/9) of 
controls (Figure 2O; p < 0.01). These data indicate that Aarssti/sti HSCs have impaired self-
renewal potential in vivo.
We next sought to determine whether reduced proteome quality preferentially impaired HSC 
function or whether it also impaired the function of restricted progenitors. In contrast to 
HSCs, we observed no significant increase in ubiquitylated protein among Aarssti/sti myeloid 
progenitors (Figures S3A–S3D). This observation is consistent with previous reports that 
rapidly dividing cells efficiently dilute out misfolded proteins (Lee et al., 2006). Because 
Aarssti/sti myeloid progenitors do not accumulate more ubiquitylated proteins than controls, 
we are precluded from making direct conclusions on the effect of reduced protein quality 
within those populations. We thus tested whether CD150−CD48−LSK MPPs (short-term 
HSCs), a progenitor cell population with similar cycling kinetics as HSCs (Oguro et al., 
2013), would be susceptible to an accumulation of ubiquitylated proteins. Indeed, similar to 
HSCs, Aarssti/sti MPPs exhibited a significant ~16% increase in ubiquitylated protein 
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compared to controls (Figure S3E; p < 0.05). However, in contrast to HSCs, we observed no 
significant change in MPP frequency (Figure S3F). To test MPP function, we competitively 
transplanted 50 Aarssti/sti or control MPPs into irradiated mice (Figure S3G). Levels of 
reconstitution by Aarssti/sti MPPs were indistinguishable from controls (Figure S3H). 
Although HSC defects largely appeared during serial transplantation, it is not possible to 
perform secondary transplants with MPPs because they lack serial reconstituting activity. 
Nevertheless, these data suggest that HSCs are particularly sensitive to disruptions in 
proteostasis, as modest declines in protein quality preferentially impair HSC self-renewal.
Accumulation of Misfolded Proteins Overwhelms and/or Impairs the Proteasome in HSCs
An accumulation of misfolded and unfolded proteins can activate proteotoxic stress response 
pathways, including the endoplasmic reticulum unfolded protein response (UPRER) (Walter 
and Ron, 2011). Basal activity of the UPRER can promote HSC survival and engraftment 
(Chapple et al., 2018; Liu et al., 2019; van Galen et al., 2018). Under more severe stress 
conditions, activation of the UPRER can induce apoptosis within HSCs (van Galen et al., 
2014) and fetal HSC self-renewal depends upon bile acids to suppress UPRER activation 
(Sigurdsson et al., 2016). This raised the question of whether the reduced HSC number in 
Aarssti/sti mice was a consequence of activation of the UPRER and increased cell death. To 
test this, we performed RNA sequencing on Aarssti/sti and control HSCs (Figure 3A) and 
looked for changes in the expression of gene sets related to the UPRER. We observed no 
significant changes in the expression of UPRER-related gene sets in Aarssti/sti compared to 
control HSCs (Figure 3B). Consistent with this observation, Aarssti/sti HSCs did not exhibit 
increased abundance of phosphorylated (Ser51) Eif2α (Figure 3C), which is one marker of 
UPRER activation (Harding et al., 1999). In addition, there was no significant difference in 
the frequency of Annexin V+ HSCs between Aarssti/sti and control mice (Figure 3D), 
indicating that reduced HSC numbers in Aarssti/sti mice are not due to increased cell death.
In the absence of detectable UPRER activation, we sought to uncover other potential 
mechanisms contributing to Aarssti/sti HSC dysfunction. Proteostasis, in addition to protein 
biogenesis, is maintained by an integrated network of physiological mechanisms that 
promote protein folding, repair, and degradation (Labbadia and Morimoto, 2015; Figure 3E). 
Previous work has demonstrated that overexpression of aggregation-prone proteins can 
overwhelm and/or impair the ubiquitin proteasome system in HEK293 cells (Bence et al., 
2001). Because HSCs exhibited less proteasome activity than restricted progenitors (Figure 
3F), we hypothesized that an accumulation of misfolded proteins might overwhelm the 
capacity of the proteasome within HSCs to efficiently degrade all ubiquitylated substrates.
To test this, we used UbG76V-GFP proteasome reporter mice (Lindsten et al., 2003). 
UbG76V-GFP mice ubiquitously express GFP that is fused to a constitutive degradation 
signal. GFP transcripts can be detected in various tissues, but no GFP fluorescence is 
detected because the protein is rapidly degraded by the proteasome. However, administration 
of a proteasome inhibitor leads to robust GFP fluorescence (Figure 3G; Lindsten et al., 
2003). Similar to other cell types, UbG76V-GFP HSCs did not express significant GFP 
fluorescence in vivo (Figure 3H). We crossed UbG76V-GFP mice to Aarssti/sti mice and 
assessed GFP expression within HSCs. Strikingly, we observed a significant accumulation of 
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GFP+ HSCs within UbG76V-GFP;Aarssti/sti mice (Figure 3H; p < 0.01), and this was not due 
to a reduction in proteasome activity (Figure 3I). These data indicate that the proteasome can 
become overwhelmed and/or impaired when misfolded proteins accumulate within HSCs.
To test if insufficient proteasome activity impairs HSC maintenance, we treated mice with 
bortezomib for 3 consecutive days and assessed HSC numbers in the bone marrow on day 4. 
Mice treated with bortezomib exhibited a ~50% reduction in HSCs compared to vehicle 
(DMSO)-treated controls (Figure 3J; p < 0.01). The bortezomib-mediated decline in HSCs 
was similar to the decline in HSCs observed within Aarssti/sti mice (Figure 2F). These data 
indicate that impaired proteasome activity impairs HSC maintenance and suggest that the 
decline in Aarssti/sti HSCs may be caused by their overwhelmed/impaired proteasome.
Accumulation of Misfolded Proteins Is Associated with c-Myc Accumulation in HSCs
In addition to regulating proteostasis, the ubiquitin proteasome system post-translationally 
regulates the abundance of multiple proteins that affect diverse cellular functions, including 
HSC fate (Moran-Crusio et al., 2012). As a consequence, we wondered if overwhelming the 
proteasome might lead to stabilization of some of these proteasome targets within HSCs. 
Our RNA sequencing data revealed a significant increase in the expression of cell cycle 
genes within Aarssti/sti HSCs (Figure 3B). In accordance with these gene expression studies, 
we determined that Aarssti/sti HSCs exhibited increased proliferation in vivo compared to 
controls. After a 72-h pulse of bromodeoxyuridine (BrdU) in vivo, 41.5% of Aarssti/sti HSCs 
incorporated BrdU compared to 23.8% of control HSCs (Figure 3K; p < 0.05).
Because Aarssti/sti HSCs exhibited increased proliferation (Figure 3K) and diminished self-
renewal activity (Figures 2N and 2O), we sought to identify known proteasome-regulated 
targets that could contribute to these phenotypes. The target that we focused on was c-Myc. 
c-Myc has an established role in regulating HSC quiescence, cell cycle entry, and self-
renewal. Although Myc is transcribed at similar levels in HSCs and progenitors, the c-Myc 
protein is mostly absent from HSCs but accumulates in more differentiated progenitors 
(Reavie et al., 2010). Conditional deletion of the E3 ubiquitin ligase Fbxw7 leads to an 
accumulation of c-Myc protein within HSCs (Reavie et al., 2010; Thompson et al., 2008), 
suggesting that Fbxw7 targets c-Myc for degradation. Fbxw7−/− HSCs exhibit increased 
cycling and premature exhaustion (Matsuoka et al., 2008; Thompson et al., 2008), which is 
similar to HSCs with enforced expression of c-Myc (Wilson et al., 2004). Genetic 
inactivation of one allele of Myc is sufficient to partially rescue Fbxw7−/− HSCs (Reavie et 
al., 2010). These studies indicate that proteasome-mediated degradation of c-Myc is 
essential for normal HSC quiescence and self-renewal.
Given that c-Myc is heavily regulated by the proteasome, promotes HSC cell cycle entry, 
and influences HSC self-renewal, we investigated whether c-Myc was dysregulated in 
Aarssti/sti mice. We determined that Aarssti/sti HSCs/MPPs expressed elevated amounts of c-
Myc protein relative to controls (Figure 3L), but no such changes were evident within 
restricted progenitors (Figure 3M). The increase in the c-Myc protein could not be explained 
by increased Myc mRNA expression, which was unchanged within Aarssti/sti HSCs (Figure 
3N). Increased c-Myc expression also could neither be explained by reduced expression of 
Fbxw7 nor any other E3 ubiquitin ligases implicated in c-Myc ubiquitylation (Figures 3O 
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and S4H–S4S). Although we cannot rule out all possible mechanisms, our data suggest that 
c-Myc accumulates within Aarssti/sti HSCs at least in part because of impaired degradation 
as a consequence of overwhelmed and/or impaired proteasome capacity.
To further support our findings in Aarssti/sti HSCs, we tested whether an accumulation of 
misfolded and unfolded proteins had similar effects on proteasome capacity and c-Myc 
expression in Pten-deficient HSCs that accumulate ubiquitylated proteins as a consequence 
of increased protein synthesis (Figure 1O). Consistent with our observations in Aarssti/sti 
HSCs, Pten-deficient HSCs exhibited a robust increase in c-Myc protein expression (Figure 
S4B) without any increase in Myc mRNA expression (Figure S4C) or decline in Fbxw7 
expression (Figure S4D). In addition, we observed a significant increase in GFP+ HSCs 
within Mx1-Cre+;Ptenfl/fl;UBG76V-GFP mice (Figure S4E), indicating that Pten-deficient 
HSCs also experience an overwhelming or impairment of their proteasome without any 
significant change in overall proteasome capacity (Figure S4F). Notably, the Rpl24Bst/+ 
mutation reduced the abundance of c-Myc in Pten-deficient HSCs/MPPs to near wild-type 
levels (Figure S4G). Taken together, these data strongly suggest that a modest accumulation 
of misfolded proteins is sufficient to overwhelm the capacity of the proteasome within HSCs 
and is associated with accumulation of c-Myc.
Reducing c-Myc Expression Partially Rescues Self-Renewal Defects in Aarssti/sti HSCs
Because c-Myc overexpression can impair HSC self-renewal, we hypothesized that c-Myc 
accumulation within Aarssti/sti HSCs was contributing to defects in serial reconstituting 
activity. To test this, we sought to reduce c-Myc expression within Aarssti/sti HSCs. We 
could not completely delete Myc because Myc deficiency causes severe hematopoietic 
defects (Wilson et al., 2004). We, thus, sought to reduce c-Myc expression by conditionally 
deleting a single allele of Myc in Aarssti/sti mice by breeding Mx1-Cre+;Mycfl/+;Aarssti/sti 
(Aarssti/sti;Myc+/−) mice. Remarkably, c-Myc expression in Aarssti/sti HSCs was reduced to 
near wild-type levels in Aarssti/sti;Myc+/− HSCs (Figure 4A), whereas levels of ubiquitylated 
protein were still elevated (data not shown).
To test if reducing c-Myc expression could partially rescue Aarssti/sti HSC self-renewal, we 
performed serial long-term reconstitution assays. We competitively transplanted 5×105 Mx1-
Cre+;Mycfl/+;Aarssti/sti, Aarssti/sti or wild-type control bone marrow cells (CD45.2+) together 
with 5 × 105 congenic bone marrow cells (CD45.1+) into lethally irradiated mice (CD45.1+) 
(Figure 4B). Similar to our HSC transplants (Figure 2M), long-term hematopoietic 
reconstitution from Aarssti/sti bone marrow cells was statistically indistinguishable from 
controls in primary recipients (Figure 4C). Aarssti/sti;Myc+/− bone marrow cells also gave 
similar levels of reconstitution in primary transplants, although they did exhibit a slight, but 
significant reduction in B cell reconstitution. After 16 weeks, 3 × 106 bone marrow cells 
from primary recipient mice were serially transplanted into lethally irradiated mice. 
Secondary recipients of Aarssti/sti bone marrow cells exhibited significantly less donor cell 
reconstitution in all lineages after transplantation (Figure 4D). Strikingly, reducing c-Myc 
expression in Aarssti/sti;Myc+/− HSCs partially prevented these defects (Figure 4D). 
Aarssti/sti;Myc+/− cells gave similar levels of reconstitution as wild-type cells, except in the 
B cell lineage where reconstitution was still reduced (Figure 4D). Overall, long-term 
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multilineage reconstitution in secondary transplants was reduced from 95% (35/37) in 
recipients of wild-type cells to 39% (17/44) in recipients of Aarssti/sti cells (p < 0.001), but 
was increased back to 94% (16/17) in recipients of Aarssti/sti;Myc+/− cells (Figure 4E; p < 
0.001). These data indicate that reducing c-Myc expression partially prevents self-renewal 
defects within Aarssti/sti HSC, and suggest that c-Myc accumulation contributes to impaired 
HSC function when proteostasis is perturbed.
DISCUSSION
Low protein synthesis is a broadly conserved feature of somatic stem cells (Blanco et al., 
2016; Llorens-Bobadilla et al., 2015; Sanchez et al., 2016; Signer et al., 2014; Zismanov et 
al., 2016) that promotes regeneration in multiple tissues. However, little is known about why 
stem cells depend upon low protein synthesis and why modest increases in protein synthesis 
impair stem cell function. In this study, we set out to address this question by examining the 
influence of protein synthesis on protein quality and homeostasis. We found that HSCs 
contain less ubiquitylated and unfolded protein than restricted myeloid progenitors in vivo 
(Figure 1) and that modest increases in protein synthesis reduce protein quality within 
HSCs. To investigate the consequences of reduced protein quality on HSCs independent of 
changes in protein synthesis rate, we examined Aarssti/sti mice that have a defect in tRNA 
editing activity. The accumulation of defective translational products within Aarssti/sti HSCs 
impaired their serial long-term multilineage reconstituting activity (Figure 2). Surprisingly, 
we found that the accumulation of misfolded proteins overwhelmed and/or impaired the 
proteasome and led to increased c-Myc abundance in both Aarssti/sti and Pten-deficient 
HSCs (Figures 3 and S4). Reducing c-Myc expression by deleting a single allele of Myc 
partially prevented the self-renewal defects observed in Aarssti/sti HSCs (Figure 4). Overall, 
our studies indicate that stem cells depend upon low protein synthesis to maintain proteome 
quality and that modest accumulation of misfolded proteins preferentially impairs HSC self-
renewal.
Our finding that the proteasome gets overloaded and impaired in HSCs raises the possibility 
that stem cells may depend on alternative mechanisms to detoxify and eliminate misfolded 
proteins. One possibility is that HSCs preferentially depend upon autophagy to degrade 
misfolded proteins. In support of this possibility, two recent studies reported that autophagy 
promotes proteostasis maintenance within aging neural stem cells (Leeman et al., 2018) and 
muscle satellite cells (García-Prat et al., 2016). Similar to HSCs, quiescent neural stem cells 
also contain less proteasome activity than restricted progenitors and neural stem cells 
preferentially store misfolded proteins as aggregates in lysosomes (Leeman et al., 2018). 
Several studies have demonstrated an essential role for autophagy in HSCs (Ho et al., 2017; 
Liu et al., 2010; Mortensen et al., 2011; Warr et al., 2013), but to our knowledge, whether 
autophagy promotes proteostasis maintenance within HSCs is unstudied.
In addition to degradation pathways, HSCs could eliminate misfolded proteins through 
proliferation. Cell division enables cells to dilute out misfolded proteins by distributing them 
to daughter cells. We determined that a buildup of misfolded proteins led to an accumulation 
of c-Myc and increased proliferation in HSCs but not restricted progenitors (Figure 3). 
These data reveal a stem-cell-specific molecular mechanism connecting the proteostasis 
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network to cell cycle control. An intriguing possibility is that HSCs sense changes in protein 
synthesis and homeostasis by proteasome-mediated turnover of c-Myc, and c-Myc 
accumulation could be an adaptive mechanism used by individual HSCs to restore 
proteostasis within daughter stem cells generated by self-renewing divisions. Furthermore, 
this mechanism could also protect the HSC pool because HSCs unable to restore proteostasis 
would have sustained c-Myc expression, which promotes HSC differentiation (Wilson et al., 
2004).
c-Myc is not the only protein in HSCs whose expression is regulated by the proteasome 
(Moran-Crusio et al., 2012). Interestingly, a previous report determined that expression of 
p53, which is also heavily regulated by the proteasome in HSCs (Abbas et al., 2010), is 
elevated within Pten-deficient HSCs and contributes to self-renewal defects in that 
background (Lee et al., 2010). Deleting a single allele of Myc also modestly restores long-
term multilineage, reconstituting activity within Pten-deficient HSCs (data not shown). 
Overwhelming of the proteasome due to an accumulation of misfolded and unfolded 
proteins is likely to have more widespread effects on HSC proteome content. However, 
detailed proteomic analyses needed to broadly investigate this possibility remain technically 
difficult to perform within rare HSCs.
Disrupted proteostasis is a hallmark of aging (López-Otín et al., 2013), but whether it 
contributes to HSC aging is still untested. An intriguing possibility is that disrupted 
proteostasis in aging HSCs could contribute to HSC dysfunction and the increased incidence 
of blood cancer in the elderly by preventing the degradation of c-Myc. A potential role for c-
Myc in stem cell aging could extend a recent study that demonstrated that reducing Myc 
expression enhances longevity in mice (Hofmann et al., 2015).
Low protein synthesis is a shared feature of many types of somatic stem cells (Blanco et al., 
2016; Llorens-Bobadilla et al., 2015; Sanchez et al., 2016; Signer et al., 2014; Zismanov et 
al., 2016). Our findings raise the possibility that the maintenance of proteostasis is similarly 
required by stem cells in diverse tissues. Interestingly, interventions that reduce protein 
synthesis and enhance proteostasis extend organismal lifespan in an evolutionary conserved 
manner (Taylor and Dillin, 2011). Our current findings suggest that mechanisms that 
promote organismal longevity are conserved at the cellular level to maintain long-lived stem 
cells in vivo.
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Dr. Robert Signer (rsigner@ucsd.edu). TMI was synthesized 
by Dr. Yuning Hong and is available from her upon request (Y.Hong@latrobe.edu.au).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice—C57BL/6J, C57BL6.SJL, Ptenfl/fl, Mx1-Cre, Rpl24Bst/+, Aarssti/sti, UbG76V-GFP, 
and Mycfl mice were housed in pathogen-free conditions.
Jose et al. Page 11
Cell Rep. Author manuscript; available in PMC 2020 February 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ptenfl/fl (Groszer et al., 2006), and Mycfl mice (de Alboran et al., 2001) were bred to Mx1-
Cre (Cre+) (Kühn et al., 1995) mice to generate Mx1-Cre+;Ptenfl/fl and Mx1-Cre+;Mycfl 
mice, respectively. Mx1-Cre+;Ptenfl/fl mice were further crossed to Rpl24Bst/+ mice (Oliver 
et al., 2004) to yield Mx1-Cre+;Ptenfl/fl;Rpl24Bst/+ mice. Aarssti/sti mice (Lee et al., 2006) 
were bred to Mx1-Cre+;Mycfl mice to produce Mx1-Cre+;Mycfl/+;Aarssti/sti mice. Mx1-Cre
+;Ptenfl/fl and Aarssti/sti were bred to UbG76V-GFP mice (Lindsten et al., 2003) to generate 
Mx1-Cre+;Ptenfl/fl;UBG76V-GFP and UbG76V-GFP;Aarssti/sti mice, respectively. Mutant 
mice were all backcrossed for at least ten generations onto a C57BL background. C57BL6/J 
(CD45.2) and C57BL6.SJL (CD45.1) mice were used in transplantation experiments.
Both male and female mice between 6 and 12 weeks of age were used in these studies. All 
mice were housed in the vivarium at the UC San Diego Moores Cancer Center. All protocols 
were approved by the UC San Diego Institutional Animal Care and Use Committee.
Cell isolation—Bone marrow cells were isolated by flushing the long bones (femurs and 
tibias) or by crushing the long bones, vertebrae and pelvic bones with a mortar and pestle in 
Ca2+- and Mg2+-free Hank’s buffered salt solution (HBSS; Corning) supplemented with 2% 
(v/v) heat-inactivated bovine serum (GIBCO). Spleens were prepared by crushing tissues 
between frosted slides. All cells were filtered through a 40 μm cell strainer to obtain single 
cell suspensions. Cell number and viability were assessed with a hemocytometer based on 
trypan blue exclusion.
METHOD DETAILS
PIPC treatment—Expression of Mx1-Cre was induced by three or four intraperitoneal 
injections of 10 mg polyinosinic-polycytidylic acid (pIpC; GE Healthcare) administered 
every other day, beginning at approximately 6 weeks of age.
Proteasome inhibition—For proteasome inhibition experiments, mice were administered 
bortezomib (Cell Signaling; 1 mg/kg) diluted in 10% (v/v) DMSO via retro-orbital injection.
Flow cytometry and sorting—For flow cytometric analysis and isolation of specific 
hematopoietic progenitors, cells were incubated with combinations of antibodies to the 
following cell-surface markers, conjugated to FITC, PE, PerCP-Cy5.5, APC, PE-Cy7, 
eFluor 660, Alexa Fluor 700, APC-eFluor 780 or biotin (antibody clones are given in 
brackets in the following list): CD3ε (17A2), CD4 (GK1.5), CD5 (53–7.3), CD8α (53–6.7), 
CD11b (M1/70), CD16/32 (FcγRII/III; 93), CD34 (RAM34), CD43 (R2/60), CD45.1 (A20), 
CD45.2 (104), CD45R (B220; RA3–6B2), CD48 (HM48–1), CD71 (R17217), CD117 (cKit; 
2B8), CD127 (IL7Rα; A7R34), CD150 (TC15–12F12.2), Ter119 (TER-119), Sca-1 (D7, 
E13–161.7), Gr-1 (RB6–8C5) and IgM (II/41). For isolation of HSCs and MPPs, Lineage 
markers included CD3, CD5, CD8, B220, Gr-1 and Ter119. For isolation of CMPs, GMPs 
and MEPs, these Lineage markers were supplemented with additional antibodies against 
CD4 and CD11b. Biotinylated antibodies were visualized by incubation with PE-Cy7 
conjugated streptavidin. All reagents were acquired from eBiosciences, or BioLegend. All 
incubations were for 30–90 min on ice.
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HSCs, MPPs, CD34+CD16/32lowCD127−Lineage−Sca-1−c-kit+ CMPs (Akashi et al., 2000), 
CD34+CD16/32highCD127−Lineage−Sca-1−c-kit+ GMPs (Akashi et al., 2000), and 
CD34−CD16/32−/lowCD127−Lineage−Sca-1−c-kit+ MEPs (Akashi et al., 2000) were pre-
enriched by selecting c-kit+ cells using paramagnetic microbeads and an autoMACS 
magnetic separator (Miltenyi Biotec) before sorting.
Non-viable cells were excluded from sorts and analyses using 4’,6-diamidino-2-
phenylindole (DAPI). Apoptotic cells were identified using APC annexin V 
(BDBiosciences). Proliferation was assessed by administering 5-bromo-2′-deoxyuridine 
(BrdU; Sigma) to mice. BrdU dissolved in PBS was administered with an initial 
intraperitoneal injection (2 mg) and then mice were maintained on drinking water containing 
1 mg/ml BrdU for 72 h. BrdU incorporation in HSCs was measured using the APC BrdU 
Flow Kit (BD Biosciences).
For analysis of ubiquitylated protein following cell surface staining, cells were fixed in 0.5 
mL of 1% paraformaldehyde (Affymetrix) in PBS for 10–15 min on ice. Cells were washed 
in PBS, then permeabilized in 200 mL PBS supplemented with 3% (v/v) fetal bovine serum 
(Life Technologies) and 0.1% (m/v) saponin (Sigma) for 5 min at room temperature (20–
25°C). Cells were then incubated with anti-ubiquitylated protein antibody (clone FK2, 
Millipore) at a concentration of 1:500 for 30 min at room temperature. This was followed by 
incubation with anti-mouse Alexa Fluor 488 (Thermo Scientific) at a concentration of 1:500 
for 30 min at room temperature. Cells were washed twice in PBS supplemented with 3% 
fetal bovine serum and 0.1% saponin, then resuspended in PBS supplemented with DAPI (4 
mg/ml final concentration) and analyzed by flow cytometry.
Data acquisition and cell sorting were performed on a FACSAria II, LSR II or FACSCanto 
flow cytometer (BD Biosciences). Sorted fractions were typically double sorted to ensure 
high purity. Data were analyzed by FlowJo (TreeStar) software.
Competitive repopulation assay—Adult recipient mice (CD45.1) were administered a 
minimum lethal dose of radiation using a Mark I Cesium source irradiator (J.L. Sheperd) to 
deliver two doses of 550 rad (1,100 rad in total) at least 4 h apart. Cells were injected into 
the retro-orbital venous sinus of anaesthetized recipients. For competitive bone marrow 
transplants 5×105 donor and 5×105 recipient-type cells were transplanted. For HSC 
transplants 10 donor CD150+CD48−Lineage−Sca-1+c-kit+ HSCs and 2×105 recipient-type 
bone marrow cells were transplanted. Blood was obtained from the tail veins of recipient 
mice every 4 weeks for at least 16 weeks after transplantation. Red blood cells were lysed 
with ammonium chloride potassium buffer. The remaining cells were stained with antibodies 
against CD45.2, CD45.1, CD45R (B220), CD11b, CD3 and Gr-1 to assess donor-cell 
engraftment.
For secondary transplants, 3×106 bone marrow cells collected from primary recipients were 
transplanted non-competitively into irradiated recipient mice. Primary recipients used for 
secondary transplantation had long-term multilineage reconstitution by donor cells and 
median levels of donor-cell reconstitution for the treatments from which they originated. 
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Mice that died over the course of transplantation experiments were omitted from the 
analyses.
For MPP transplants, 50 CD150−CD48−Lineage−Sca-1+c-kit+ MPPs and 2×105 recipient-
type bone marrow cells were transplanted. Blood was obtained from the tail veins of 
recipient mice 3,5 and 7 weeks after transplantation.
Western blot analysis—Equal numbers of cells from each stem or progenitor population 
were sorted into trichloracetic acid (TCA, Sigma). The final concentration was adjusted to 
10% (v/v) TCA. Extracts were incubated on ice for at least 15 min and centrifuged at 15,000 
g at 4°C for 15 min. Precipitates were washed in acetone twice and dried. The pellets were 
solubilized in 9 M urea, 2% (v/v) Triton X-100, and 1% DTT. LDS loading buffer (Life 
Technologies) was added and the pellet was heated at 70°C for 10 min. Samples were 
separated on Bis-Trispolyacrylamide gels (Life Technologies) and transferred to PVDF 
membranes (Bio-Rad). Western blot analyses were performed according to the protocol from 
Cell Signaling Technologies. Blots were stripped with 1% SDS, 25 mM glycine (pH 2) 
before re-probing. The following primary and secondary antibodies were used for western 
blot analyses: Ubiquitin (P4D1; Cell Signaling), K48-Ubiquitin (polyclonal; Cell Signaling 
4289), c-Myc (polyclonal; Cell Signaling 9402S), phos-Eif2α (S51; Cell Signaling) β-Actin 
(AC74; Sigma), Gapdh (14C10; Cell Signaling), HRP-linked anti-rabbit IgG (Cell 
Signaling) and HRP-linked anti-mouse IgG (Cell Signaling). Blots were developed with the 
SuperSignal West Femto or Pico PLUS chemiluminescence kit (Thermo Scientific).
Measurement of unfolded proteins—4×106 bone marrow cells were stained for cell 
surface markers as described above. After staining, cells were washed twice in Ca2+- and 
Mg2+-free PBS. Tetraphenylethene maleimide (TMI; stock 2 mM in DMSO) was diluted in 
PBS (50 μM final concentration), added to each sample and samples were incubated at 37°C 
for 45 minutes. Samples were washed twice in PBS and analyzed by flow cytometry. DAPI 
was omitted from these samples because of spectral overlap.
To assess the effects of heat shock, 106 BM cells were incubated Ca2+- and Mg2+-free HBSS 
(Corning) supplemented with 2% heat-inactivated bovine serum at 37°C or 42°C for 4 h. 
Cells were then washed twice in Ca2+- and Mg2+-free PBS (Corning), and TMI was added 
as described above.
In vivo measurement of protein synthesis—OP-Puro (Medchem Source; 50 mgkg−1 
body mass; pH 6.4–6.6 in PBS) was injected intraperitoneally. One hour later mice were 
euthanized. Bone marrow was collected, and 4×106 cells were stained with combinations of 
antibodies against cell-surface markers as described above. After washing, cells were fixed 
in 0.5 mL of 1% paraformaldehyde (Affymetrix) in PBS for 10–15 min on ice. Cells were 
washed in PBS, then permeabilized in 200 mL PBS supplemented with 3% (v/v) fetal 
bovine serum (Life Technologies) and 0.1% (m/v) saponin (Sigma) for 5 min at room 
temperature (20–25°C). The azide-alkyne cycloaddition was performed using the Click-iT 
Cell Reaction Buffer Kit (Life Technologies) and azide conjugated to Alexa Fluor 555 (Life 
Technologies) at 5 mM final concentration. After the 30-min reaction, the cells were washed 
twice in PBS supplemented with 3% fetal bovine serum and 0.1% saponin, then resuspended 
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in PBS supplemented with DAPI (4 mgml−1 final concentration) and analyzed by flow 
cytometry (Hidalgo San Jose and Signer, 2019).
In vitro analysis—Colony forming units were assessed by sorting 500 live bone marrow 
cells per well of a 96-well plate (24 wells per mouse) containing methylcellulose culture 
medium (M3434; STEMCELL Technologies). Colonies were counted after 14 days.
Cell volume—Average diameter was measured by sorting cells into flat-bottom 96-well 
plates and analyzing micrographs with ImageJ software. Cell volume was calculated based 
on the assumption that cells are spherical (4/3*π*r3).
Protein content—Equal numbers of cells from each stem or progenitor population were 
sorted into HBSS supplemented with 2% (v/v) heat-inactivated bovine serum (GIBCO). 
Samples were washed once with PBS and centrifuged at 2500 g at 4°C for 5 min. 
Supernatant was discarded and protein pellets were directly lysed and solubilized in 9M 
urea, 2% SDS, 50 mM DTT, and 50 mM Tris pH 7.4. After incubating the samples for 10–
15 min at room temperature, LDS loading buffer (Life Technologies) was added and the 
sample was heated at 70°C for 10 minutes. Samples were separated on Bis-
Trispolyacrylamide gels (Life Technologies). The Bis-Trispolyacrylamide gels were then 
stained with SYPRO Ruby Protein Gel Stain (Bio-Rad) for 3 h and washed in a solution 
containing 7% acetic acid and 10% methanol for 1 h. Gels were imaged using Gel Doc XR 
(Bio-Rad) and analyzed with Image Lab 6.0.1 software (Bio-Rad).
For bone marrow cells, incubated at 37°C or 42°C, 105 cells were sorted into TCA. The final 
concentration was adjusted to 10% TCA. Extracts were incubated on ice for at least 15 min 
and centrifuged at 15,000 g at 4°C for 15 min. Precipitates were washed in acetone twice 
and dried. The pellets were solubilized in 6 M urea, 2% (v/v) Triton X-100, and 1% (v/v) 2-
mercaptoethanol. The protein content in the supernatant was assessed with the microBCA 
assay (Pierce).
Proteasome activity—5×103 cells from each cell population were plated into 96-well 
plates in triplicate. Proteasome activity was measured with the Proteasome-Glo 
chymotrypsin-like cell based assay (Promega). Luminescence was monitored after a 15 min 
incubation using a Synergy HTX multi-mode plate reader. HSCs/MPPs incubated with 100 
μM MG132 were used as controls.
RNA sequencing—For RNA-seq analysis, total RNA was extracted from ~3000 HSCs 
using the RNeasy Plus Micro Kit (QIAGEN). Illumina mRNA libraries were prepared using 
the SMARTseq2 protocol (Picelli et al., 2014). 2.6 μL of total RNA was used in the 
SMARTSeq2 protocol (70pg to 1.62ng). 18 cycles of PCR were performed for the cDNA 
preamplification step and 12 cycles were performed for the tagmentation library preparation. 
The resulting libraries were pooled and deep sequenced in two lanes on the Illumina HiSeq 
2500 in high output mode using single-end reads with lengths of 50 nucleotides (25–35M 
reads per condition). The single-end reads that passed Illumina filters were filtered for reads 
aligning to tRNA, rRNA, adaptor sequences, and spike-in controls. The reads were then 
aligned to the mm10 reference genome using TopHat (v 1.4.1) (Trapnell et al., 2009). DUST 
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scores were calculated with PRINSEQ Lite (v 0.20.3) (Schmieder and Edwards, 2011) and 
low-complexity reads (DUST > 4) were removed from the BAM files. The alignment results 
were parsed via the SAMtools (Li et al., 2009) to generate SAM files. Read counts to each 
genomic feature were obtained with the htseq-count program (v 0.7.1) (Anders et al., 2015) 
using the “union” option. After removing absent features (zero counts in all samples), the 
raw counts were then imported to Bioconductor package DESeq2 (v 1.6.3) (Love et al., 
2014) to identify differentially expressed genes among samples. P values for differential 
expression are calculated using the Wald test for differences between the base means of two 
conditions. These P values are then adjusted for multiple test correction using Benjamini 
Hochberg algorithm. We considered genes differentially expressed between two groups of 
samples when the DESeq2 analysis resulted in an adjusted P value of < 0.10 and the 
difference in gene expression was at least 2-fold. Principal Component Analysis (PCA) was 
performed using the ‘prcomp’ function in R. Heatmaps of differentially expressed genes 
were generated from log2(RPKM+1) values using the function heatmap.2(package gplots) in 
R. GSEA with classic scoring scheme was run for the geneset Biological processes 
(c5.bp.v6.1.symbols.gmt) from MSigDB on pre-ranked gene lists. For genes with 
log2FoldChange greater than zero, a rank −log10(pValue) was assigned and for genes with 
log2FoldChange less than zero, a rank of log10(pValue) was assigned.
Quantitative PCR—Cells were sorted directly into RLT plus buffer (QIAGEN) 
supplemented with 2-mercaptoethanol. RNA was extracted with the RNeasy micro plus kit 
(QIAGEN) and cDNA was synthesized with the RT2 First Strand Kit (QIAGEN). Reactions 
were run in 20 μL volumes with SYBR green and a LightCycler 480 (Roche Applied 
Science). Primer sequences were: Myc F, 5′- CTTCTCTCCTTCCTCGGACTC-3′; Myc R 
5′- GGAGATGAGCCCGACTCCGACCTC-3′; β-Actin F, 5′-
CGTCGACAACGGCTCCGGCATG-3′; β-Actin R, 5′-GGGCC 
TCGTCACCCACATAGGAG-3′
QUANTIFICATION AND STATISTICAL ANALYSIS
Group data are represented by mean ± standard deviation, except for transplantation data 
which are represented as mean ± standard error of the mean. To test statistical significance 
between two samples, two-tailed Student’s t tests were used. When multiple samples were 
compared, statistical significance was assessed using a one-way ANOVA or a repeated-
measures one-way ANOVA (when comparing multiple time points or populations from the 
same mouse) followed by Dunnett’s test for multiple comparisons. Statistical significance 
comparing overall numbers of mice with long-term multilineage reconstitution was assessed 
by a Fisher’s exact test. Statistical tests were performed using GraphPad Prism software. 
The specific type of test used for each figure panel is described in the figure legends, except 
for the RNA sequencing data which is described in the “RNA sequencing” paragraph of the 
STAR Methods section above.
For normalized data, means were calculated and statistical tests were performed using 
log10-transformed data and then means were back-transformed to prevent data skewing. No 
randomization or blinding was used in any experiments. The only mice excluded from any 
experiment were those that died after transplantation.
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DATA AND CODE AVAILABILITY
The RNA-sequencing data comparing Aarssti/sti and control HSCs is available at Gene 
Expression Omnibus: GSE141008.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• HSCs have fewer misfolded and unfolded proteins than restricted myeloid 
progenitors in vivo
• HSCs depend on low protein synthesis to maintain their elevated proteome 
quality
• tRNA editing defect impairs HSC self-renewal by increasing genesis of 
misfolded proteins
• Misfolded proteins overwhelm proteasome in HSCs, leading to c-Myc 
accumulation
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Figure 1. HSCs Depend upon Low Protein Synthesis to Maintain Proteome Quality
(A) Western blot examining ubiquitylated protein in 3 × 104 HSCs/MPPs, CMPs, GMPs, 
and MEPs (one of >5 blots).
(B) Flow cytometry analysis showing ubiquitylated protein content relative to HSCs (n = 11 
mice).
(C) Representative histograms of ubiquitylated protein content in HSCs, CMPs, GMPs, and 
MEPs.
(D) Cell volume of HSCs, CMPs, GMPs, and MEPs (n ≥ 34 cells/population).
(E) Representative gel showing total protein content following SYPRO Ruby staining in 
HSCs/MPPs, CMPs, GMPs, and MEPs (one of 4 blots).
(F) Total protein content relative to HSCs (n = 4 experiments).
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(G) Ubiquitylated protein relative to total protein content in HSCs, CMPs, GMPs, and MEPs 
(from B and E).
(H) Diagram showing that TMI fluoresces when it binds to free cysteine thiols in unfolded 
proteins.
(I) Relative TMI fluorescence in bone marrow cells after a 4-h incubation at 37°C or 42°C (n 
= 8 mice).
(J) Total protein content in bone marrow cells after a 4-h incubation at 37°C or 42°C (n = 3 
mice).
(K) TMI fluorescence in bone marrow cells from mice treated 18 h earlier with bortezomib 
(BZ) or vehicle (DMSO) (n = 6 mice/treatment).
(L) Relative TMI fluorescence in HSCs and progenitors (n = 11 mice).
(M) OP-Puro incorporation by HSCs, CMPs, GMPs, and MEPs in vivo (n = 4 mice).
(N) Diagram representing effects on HSC protein synthesis in wild-type (Ptenfl/fl;Rpl24+/+), 
Pten-deficient (Mx1-Cre+Ptenfl/fl;Rpl24+/+), and Mx1-Cre+;Ptenfl/fl;Rpl24Bst/+ mice.
(O) Western blot examining ubiquitylated protein in 8.5 × 103 HSCs/MPPs from 
Ptenfl/fl;Rpl24+/+, Mx1-Cre+Ptenfl/flRpl24+/+, and Mx1-Cre+;Ptenfl/fl; Rpl24Bst/+ mice (one 
of 3 blots).
(P) TMI fluorescence in wild-type, Mx1-Cre+;Ptenfl/fl;Rpl24+/+, and Mx1-Cre
+;Ptenfl/fl;Rpl24Bst/+ mice (n = 3–4 mice/genotype).
Data represent mean ± standard deviation. Statistical significance was assessed using a 
Student’s t test (I-K) or an ANOVA followed by Dunnett’s multiple comparisons test relative 
to HSCs (B, D, F, G, L, M, and P). *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2. A tRNA Editing Defect that Reduces Proteome Quality Impairs HSC Self-Renewal
(A) Western blot examining ubiquitylated protein in 2.5 × 104 wild-type (+/+) and Aarssti/sti 
(sti/sti) HSCs/MPPs, CMPs, GMPs, and MEPs (one of 2 blots).
(B) Flow cytometry analysis showing ubiquitylated protein content in Aarssti/sti (sti/sti) 
relative to wild-type (+/+) HSCs (n = 4 mice/genotype).
(C) OP-Puro incorporation by wild-type (+/+) and Aarssti/sti (sti/sti) HSCs and progenitor 
cells in vivo (n = 3 mice/genotype).
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(D) Bone marrow cellularity (BM; 1 femur and 1 tibia) in wild-type (+/+) and Aarssti/sti (sti/
sti) mice (n = 6 mice/genotype).
(E) Frequency of HSCs in wild-type (+/+) and Aarssti/sti (sti/sti) bone marrow (n = 6 mice/
genotype).
(F and G) Absolute number of HSCs in the bone marrow (1 femur and 1 tibia; F) and spleen 
(G) of wild-type (+/+) and Aarssti/sti (sti/sti) mice (n = 6 mice/genotype).
(H-J) Frequency of CMPs (H), GMPs (I), and MEPs (J) in wild-type (+/+) and Aarssti/sti (sti/
sti) bone marrow (n = 6 mice/genotype).
(K) Frequency of colony-forming unit (CFU) progenitors in wild-type (+/+) and Aarssti/sti 
(sti/sti) bone marrow (n = 4 mice/genotype).
(L) Diagram showing HSC transplantation strategy.
(M) Donor cell engraftment when 10 HSCs from wild-type (+/+) and Aarssti/sti (sti/sti) mice 
were transplanted with 2 × 105 recipient-type bone marrow cells into irradiated mice. Total 
hematopoietic cell, B cell, T cell, and myeloid cell engraftment is shown (n = 4 donors and 
14–21 total recipients/genotype).
(N) Donor cell engraftment in secondary recipients (n = 2 donors and 8–9 total recipients/
genotype).
(O) Frequency of secondary recipients in (N) that exhibited long-term (16-week) 
multilineage reconstitution (≥0.5% donor derived peripheral blood B, T, and myeloid cells).
Data represent mean ± standard deviation (B-K) or standard error of the mean (M and N). 
Statistical significance was assessed using a Student’s t test or a Fisher’s exact test (O). *p < 
0.05; **p < 0.01; ***p < 0.001.
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Figure 3. Accumulation of Ubiquitylated Protein Overwhelms the Proteasome in Aarssti/sti 
HSCs, Leading to c-Myc Stabilization
(A) Heatmap showing 94 differentially expressed transcripts (≥ 2-fold change; padj < 0.1) 
up- (red) or downregulated (blue) between wild-type (+/+) and Aarssti/sti (sti/sti) HSCs (n = 
3 experiments/genotype).
(B) Gene set enrichment analysis demonstrating no significant activation of the UPRer in 
Aarssti/sti HSCs.
(C) Western blot examining phosphorylated (Ser51)-Eif2α in 2 × 104 wild-type (+/+) and 
Aarssti/sti (sti/sti) HSCs/MPPs.
(D) Frequency of Annexin V+ HSCs in wild-type (+/+) and Aarssti/sti (sti/sti) (n = 3 mice/
genotype).
(E) Diagram of the proteostasis network.
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(F) Proteasome activity in 5 × 103 HSCs/MPPs, CMPs, GMPs, and MEPs (n = 5–9 
replicates in 4 experiments). Data are shown in relative luminescence units (RLUs).
(G) Representative histogram showing GFP expression in ubG76V-GFP HSCs/MPPs in vitro 
treated for 18 h with (gray) or without (black) BZ.
(H) Frequency of HSCs that are GFP+ in UbG76V-GFP (+/+) and UbG76V-GFP;Aarssti/sti 
(sti/sti) bone marrow (n = 4–5 mice/genotype).
(I) Relative proteasome activity in wild-type (+/+) and Aarssti/sti (sti/sti) HSCs/MPPs (n = 9 
replicates in 3 experiments).
(J) Number of HSCs in the bone marrow (1 femur and 1 tibia) in mice treated with BZ or 
vehicle (DMSO) (n = 5–6 mice/treatment).
(K) Frequency of wild-type (+/+) and Aarssti/sti (sti/sti) HSCs that incorporated BrdU after a 
72-h pulse in vivo (n = 6–8 mice/genotype).
(L and M) Western blot examining c-Myc protein in 104 HSCs/MPPs (L) or 1.8 × 104 
CMPs, GMPs and MEPs (M) isolated from wild-type (+/+) and Aarssti/sti (sti/sti) mice (one 
of 2 (L) or 3 (M) blots).
(N) Myc expression normalized to β-Actin in wild-type (+/+) and Aarssti/sti (sti/sti) HSCs (n 
= 3).
(O) Fbxw7 expression in wild-type (+/+) and Aarssti/sti (sti/sti) HSCs (n = 3/genotype).
Data represent mean ± standard deviation. Statistical significance was assessed using a 
Student’s t test (D, H, I, J, K, N, and O) or an ANOVA followed by Dunnett’s test relative to 
HSCs/MPPs (F). *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 4. Reducing c-Myc Expression Largely Rescues Serial Reconstituting Activity of 
Aarssti/sti HSCs
(A) Western blot examining c-Myc in 104 HSCs/MPPs isolated from wild-type (+/+), Mx1-
Cre+;Aarssti/sti;Mycfl/+ (sti/sti;Myc+/−) and Aarssti/sti (sti/sti;Myc+/+) mice.
(B) Diagram showing bone marrow transplantation strategy.
(C) Donor cell engraftment 16 weeks after 5 × 105 bone marrow cells from wild-type (+/+), 
Aarssti/sti (sti/sti;Myc+/+) and Mx1-Cre+;Aarssti/sti;Mycfl/+ (sti/sti;Myc+/−) mice were 
transplanted with 5 × 105 recipient-type bone marrow cells into irradiated mice. Total 
hematopoietic cells, B cell, T cell, and myeloid cell engraftment is shown (n = 4–8 donors 
and 26–44 total recipients/genotype).
(D) Donor cell engraftment in secondary recipients (n = 4–10 donors and 17–44 recipients/
genotype).
(E) Frequency of secondary recipients in (D) that exhibited long-term multilineage 
reconstitution.
Data represent mean ± standard error of the mean. Statistical significance was assessed using 
a Student’s t test (C and D) or Fisher’s exact test (E). *p < 0.05; **p < 0.01; ***p < 0.001.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
APC Anti-mouse CD3ε (17A2) BioLegend Cat #100236
FITC Anti-mouse CD3ε (17A2) BioLegend Cat #100204
PE Anti-mouse CD3ε (17A2) BioLegend Cat #100206
APC Anti-mouse CD4 (GK1.5) BioLegend Cat #100412
FITC Anti-mouse CD4 (GK1.5) BioLegend Cat #100406
PE Anti-mouse CD4 (GK1.5) BioLegend Cat #100408
APC Anti-mouse CD5 (53–7.3) BioLegend Cat #100626
FITC Anti-mouse CD5 (53–7.3) BioLegend Cat #100606
PE Anti-mouse CD5 (53–7.3) BioLegend Cat #100608
APC Anti-mouse CD8α (53–6.7) eBioscience Cat #17–0081–82
FITC Anti-mouse CD8α (53–6.7) eBioscience Cat #11–0081–85
PE Anti-mouse CD8α (53–6.7) eBioscience Cat #12–0081–83
APC Anti-mouse CD11b (M1/70) eBioscience Cat #17–0112–82
APC efluor780 Anti-mouse CD11b (M1/70) eBioscience Cat #47–0112–82
FITC Anti-mouse CD11b (M1/70) eBioscience Cat #12–0112–83
PE Anti-mouse CD11b (M1/70) eBioscience Cat #11–0112–85
PE/Cy7 Anti-mouse CD16/32 (FcγRII/III; 93) BioLegend Cat #101318
PerCP/Cy5.5 Anti-mouse CD16/32 (FcγRII/III; 93) BioLegend Cat #101324
Biotin Anti-mouse CD34 (RAM34) eBioscience Cat #13–0341–85\
eFluor660 Anti-mouse CD34 (RAM34) eBioscience Cat #50–0341–82
Alexa Fluor 700 Anti-mouse CD34 (RAM34) eBioscience Cat #56–0341–82
FITC Anti-mouse CD34 (RAM34) eBioscience Cat #11–0341–85
FITC Anti-mouse CD43 (R2/60) eBioscience Cat #11–0431–85
PE Anti-mouse CD43 (R2/60) eBioscience Cat #12–0431–83
APC eFluor 780 Anti-mouse CD45.1 (A20) eBioscience Cat #47–0453–82
Alexa Fluor 700 Anti-mouse CD45.2 (104) BioLegend Cat #109822
FITC Anti-mouse CD45.2 (104) BioLegend Cat #109806
APC Anti-mouse CD45R (B220) (RA3–6B2) eBioscience Cat #17–0452–83
FITC Anti-mouse CD45R (B220) (RA3–6B2) eBioscience Cat #11–0452–85
PE Anti-mouse CD45R (B220) (RA3–6B2) eBioscience Cat #12–0452–85
PerCP-Cyanine5 Anti-mouse CD45R (B220) (RA3–6B2) eBioscience Cat #45–0452–82
APC Anti-mouse CD48 (HM48–1) BioLegend Cat #103412
FITC Anti-mouse CD48 (HM48–1) BioLegend Cat #103404
PE Anti-mouse CD48 (HM48–1) BioLegend Cat #103406
PE/Cy7 Anti-mouse CD48 (HM48–1) BioLegend Cat #103424
FITC Anti-mouse CD71 (R17217) eBioscience Cat #11–0711–85
APC Anti-mouse CD117 (cKit) (2B8) eBioscience Cat #17–1171–83
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REAGENT or RESOURCE SOURCE IDENTIFIER
APC eFluor 780 Anti-mouse CD117 (cKit) (2B8) eBioscience Cat #47–1711–82
PE-Cyanine7 Anti-mouse CD117 (cKit) (2B8) eBioscience Cat #25–1711–82
PE Anti-mouse CD127 (IL7Rα; A7R34) BioLegend Cat #135010
APC Anti-mouse CD150 (TC15–12F12.2) BioLegend Cat #115910
PE Anti-mouse CD150 (TC15–12F12.2) BioLegend Cat #115904
PE-Cyanine7 Anti-mouse CD150 (TC15–12F12.2) BioLegend Cat #115914
APC Anti-mouse Ter119 (TER-119) Biolegend Cat #116212
FITC Anti-mouse Ter119 (TER-119) Biolegend Cat #116206
PE Ter119 (TER-119) Biolegend Cat #116208
APC Anti-mouse Sca-1 (D7, E13–161.7)\ eBioscience Cat #17–5981–82
Alexa Fluor 700 Anti-mouse Sca-1 (D7, E13–161.7) eBioscience Cat #56–5981–82
FITC Anti-mouse Sca-1 (D7, E13–161.7) eBioscience Cat #11–5981–85
PerCp-Cyanine5.5 Anti-mouse Sca-1 (D7, E13–161.7) eBioscience Cat #45–5981–82
APC Anti-mouse Gr-1 (RB6–8C5) BioLegend Cat #108412
FITC Anti-mouse Gr-1 (RB6–8C5) BioLegend Cat #108406
PE Anti-mouse Gr-1 (RB6–8C5) BioLegend Cat #108408
PE/Cy7 Anti-mouse Gr-1 (RB6–8C5) BioLegend Cat #108416
APC Anti-mouse IgM (II/41) eBioscience Cat #17–5790–82
PE Anti-mouse IgM (II/41) eBioscience Cat #12–5790–83
Streptavidin-PECy7 BioLegend Cat #405206
Anti-Ubiquitin (P4D1) Cell Signaling Cat #3933S
Anti-K48-Polyubiquitin (polyclonal) Cell Signaling Cat# 4289S
Anti-c-Myc (polyclonal) Cell Signaling Cat# 9402S
Anti-phos-Eif2α (S51) Cell Signaling Cat #9721S
Anti-β-Actin (AC74) Sigma Cat #A2228
Anti-Gapdh (14C10) Cell Signaling Cat #2118S
HRP-linked anti-rabbit IgG Cell Signaling Cat #7074S
HRP-linked anti-mouse IgG Cell Signaling Cat #7076S
Chemicals, Peptides, and Recombinant Proteins
PIPC GE Healthcare Biosciences Corp Cat #27473201
Anti-mouse CD117 microbeads Miltenyi Cat #130–091–224
TCA Sigma Cat #T6399
Triton X-100 CalBiochem Cat #648466
LDS loading buffer Life Technologies Cat #NP007
SDS Life Technologies Cat #NP0060
Glycine Sigma Cat #50046
Tetraphenylethene maleimide (TMI) Dr. Yuning Hong Custom Synthesized
OP-Puro Medchem Source Custom Synthesized
SYPRO Ruby Protein Gel Stain Bio-Rad Cat #1703125
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REAGENT or RESOURCE SOURCE IDENTIFIER
2-mercaptoethanol Sigma Cat #M3148
SYBR green Roche Cat #4707516001
Critical Commercial Assays
SuperSignal West Femto or Pico PLUS chemiluminescence kit Thermo Scientific Cat #34095
Click-iT Cell Reaction Buffer Kit Life Technologies Cat #C10269
Alexa Fluor 555-conjugated azide Life Technologies Cat #A20012
Proteasome-Glo chymotrypsin-like cell based assay Promega Cat #G8660
RNeasy Plus Micro Kit QIAGEN Cat #74034
RT2 First Strand Kit QIAGEN Cat #330404
Deposited Data
RNA-sequencing data (Aarssti/sti and Aars+/+ HSCs) GEO GSE141008
Experimental Models: Organisms/Strains
Mouse: B6: C57BL/6J The Jackson Laboratory Cat #000664
Mouse: B6SJL: B6.SJL The Jackson Laboratory Cat #002014
Mouse: Ptenfl/fl The Jackson Laboratory Cat #006440
Mouse: Mx1-Cre The Jackson Laboratory Cat #003556
Mouse: Rpl24Bst/+ The Jackson Laboratory Cat #000516
Mouse: Aarssti/sti The Jackson Laboratory Cat #002560
Mouse: UbG76V-GFP The Jackson Laboratory Cat #008111
Mouse: Mycfl The Jackson Laboratory Cat #011123
Oligonucleotides
Myc forward IDT 5′- CTTCTCTCCTTCCTCGGACTC-3′
Myc reverse IDT 5′- 
GGAGATGAGCCCGACTCCGACCTC
-3′
β-Actin forward IDT 5′-
CGTCGACAACGGCTCCGGCATG-3′
β-Actin reverse IDT 5′-
GGGCCTCGTCACCCACATAGGAG-3
′
Software and Algorithms
FlowJo FlowJo, LLC N/A
FACSDiva BD Bioscience N/A
Prism 8 GraphPad N/A
ImageJ NIH N/A
Image Lab 6.0.1 Bio-Rad N/A
TopHat 1.4.1 JHU CCB N/A
PRINSEQ Lite 0.20.3 N/A N/A
Htseq-count 0.7.1 N/A N/A
Bioconductor package DESeq2 1.6.3 Bioconductor N/A
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